FeesSafety
Pluang+

OS Therapies raises $7.2M from warrant exercise to fund Herlystic™ regulatory filings in 2026

Company Fundamentals
19 Oct 2026, 15:30 WIB
Newsfile Corp
View Source
Bullish
OS Therapies raises $7.2M from warrant exercise to fund Herlystic™ regulatory filings in 2026

OS Therapies secured $7.2 million from warrant exercises by investors, providing funds to support regulatory submissions for its cancer immunotherapy Herlystic™ in the U.S., U.K., Europe, and Australia, expected in Q4 2026. The company also anticipates receiving $7 million in UK R&D tax credits by early 2027 to extend its operating runway. Herlystic™ targets osteosarcoma and has multiple FDA and EMA designations, with plans to submit a Biologics License Application and Conditional Marketing Authorisation Applications later this year. Successful approval could make OS Therapies eligible for a Priority Review Voucher, potentially generating significant revenue.

OS Therapies' recent $7.2 million warrant exercise inducement and exchange offer is noted here with Pluang's Health sector market data as of Oct 19, 2026 18:43 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 68 rose and 54 fell today. Notable movers include HIMS at USD 28.48 with a 1-day change of +1.46%, BTSG at USD 61.72 with +1.40%, and IOVA at USD 13.80 with +1.32%, with typical hold times ranging from 2 to 22 days.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
34 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
38 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
43 minutes ago
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. ...

Company Fundamentals
Bullish
43 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
43 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App